Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) recently ticked higher on strong volume. About 438367 contracts were traded on 15-Apr-19 compared to daily average volume of 249680 shares. The first sale was made at $7.03 but later the stock became weaker, and closed with a gain of 4.57%. It was last traded at $7.32 apiece.

Syros Pharmaceuticals, Inc. (SYRS): Outperform Candidate With 118.58% Upside Potential

Syros Pharmaceuticals, Inc. is maintained at an average outperform rating by 7 stock analysts, and there are at least 7.9% of shares outstanding that are currently legally short sold. The shares went down by -17.57% in value last month. Year-to-date it jumped 31.42%. Analysts are turning out to be more optimistic than before, with 6 of analysts who cover Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) advice adding it to buy candidate list. Wall Street experts also assign a $16 price target on Syros Pharmaceuticals, Inc., pointing towards a 118.58% rally from current levels. The stock is trading for about -46.99% less than its 52-week high.

Syros Pharmaceuticals, Inc. Reports -4.88% Sales Growth

Revenue scored -4.88% growth from the previous quarter, coming up with $390000.

SYRS Retreats -1.08% In A Week

This company shares (SYRS) so far managed to recover 41.59% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 5.82% while widening the period to a month, volatility was 5.61%. The share price has yet to cross its 20 days moving average, floating at a distance of -14.53% and sits -2.46% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned -1.08% losses and is down by -16.13% compared with its 200-day moving average of $7.41. Also, Syros Pharmaceuticals, Inc. (SYRS) needs to overturn a -45% decrease it experienced over the past twelve months.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Consensus Call At 0

As regular trading ended, Aclaris Therapeutics, Inc. (ACRS) stock brought in a -$0.52 drop to $5.51. The day started at a price of $6.13 but then traded as high as $6.2 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 0. Aclaris Therapeutics, Inc. is given 3 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -74.92% from their peak of $21.97 and now has a $228.11 million market value of equity.

Aclaris Therapeutics, Inc. Could Grow 474.77% More

ACRS’s mean recommendation on Reuter’s scale improved from 1.33 thirty days ago to 1.4 now, which indicates a buy consensus from the analyst community. They see Aclaris Therapeutics, Inc. (ACRS) price hitting a mean target of $31.67 a share, meaning the stock still has potential that could lift the price another 474.77% . Also, the recent close suggests the stock is underpriced by 807.44% compared to the most bullish target.

Aclaris Therapeutics, Inc. (ACRS) Returns -25.44% This Year

The company had seen its current volume reaching at 821310 shares in the last trade. That compares with the recent volume average of 392420. At the close of regular trading, its last week’s stock price volatility was 7.11% which for the month reaches 5.45%. Aclaris Therapeutics, Inc. dipped to as low as $5.9573 throughout the day and has returned -25.44% in this year. At one point in the past year, the shares traded as low as $5.49 but has recovered 0.36% since then. [T4]